Can-Fite BioPharma Ltd (NYSE American: CANF, TASE: CFBI) has received approval from Israel's Ministry of Health to conduct pre-clinical studies on cannabinoid fractions at nanomolar concentrations. This assessment aims to explore effects on cancer, inflammatory, and fat cells, potentially minimizing the adverse effects associated with higher concentrations. Can-Fite's research will be conducted in its labs, utilizing patent-pending formulations and assays. The medical cannabis market, projected to grow at a CAGR of 29%, positions Can-Fite strategically for advancements in this emerging field.
Can-Fite BioPharma Ltd. (NYSE American: CANF) announced progress on its drug candidate Namodenoson for treating non-alcoholic steatohepatitis (NASH). The company is designing a Phase IIb study with expert collaboration, following a successful Phase II study. Manufacturing for the clinical trial is complete, and new NASH patents have been issued. Namodenoson is licensed for distribution in Korea and China, targeting a growing market projected at $35-40 billion by 2025. Current estimates indicate 17%-33% of the U.S. population has non-alcoholic fatty liver disease (NAFLD), emphasizing the urgent medical need.